With regards to pathological findings, the evidence suggests that that molecular-GBM harbor higher rates of TERT-promoter mutation [8], while histological-GBM more likely harbor mutations of PTEN, TOP3A, CDK4, MYB, KIT, KRAS, and NTRK3 [6]. The gene discussed is PTEN; the disease is glioblastoma.